<DOC>
	<DOC>NCT01833494</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.</brief_summary>
	<brief_title>A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Receiving stable maintenance hemodialysis 3 times a week. Dialysis patients with hyperphosphatemia Patients having history of a pronounced brain / cardiovascular disorder. Patients having severe gastrointestinal disorders. Patients having severe hepatic disorders.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>